Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416995 | 0.85 | HTR6 (0.50) | HTR6ALDH1A1CNR2PDE4APDE4B | |
| SCHEMBL4417556 | 0.83 | PDE4A (0.39) | HTR6ALDH1A1HTTPDE4APDE4B | |
| SCHEMBL6421284 | 0.71 | CNR2 (0.57) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL8862370 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL30484777 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL25316072 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL30484776 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL25318908 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL28002722 | 0.70 | CNR2 (0.56) | ALDH1A1HTTCNR2PGRRORA | |
| SCHEMBL16822023 | 0.70 | CYP1A2 (0.59) | ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885ALDH1A1 935/4885HTT 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.